CG ONCOLOGY INC

CG Oncology’s Q2 2026 results reveal a $1 billion cash runway, strong clinical milestones in PIVOT‑006 and BOND‑003, and a BLA launch plan for NMIBC therapy.

CG Oncology, Inc. announces May investor conferences, showcasing its late‑stage bladder‑sparing immunotherapy and potential impact on bladder cancer treatment.

CG Oncology’s accelerated PIVOT‑006 Phase 3 readout boosts investor confidence, lifts analyst price targets, and positions cretostimogene as a first‑in‑class bladder‑cancer therapy.

CG Oncology’s $3.38 billion market cap and Nasdaq-listed stock is poised to advance a promising bladder‑sparing cancer therapy, highlighted at the 2026 J.P. Morgan Healthcare Conference.

CG Oncology, a late-stage biopharmaceutical company, is pioneering a groundbreaking bladder-sparing therapeutic for bladder cancer treatment, offering new hope to patients and a significant leap forward in oncology treatment methodologies.

CG Oncology, a biopharmaceutical company specializing in bladder cancer treatments, has made significant progress with its lead drug candidate, cretostimogene grenadenorepvec, showing promising results in Phase 3 clinical trials.

CG Oncology Inc. announced promising results for its lead product, cretostimogene grenadenorepvec, in treating bladder cancer, showing a 42.3% complete response rate at 24 months in high-risk patients.